As of 2025-09-16, the EV/EBITDA ratio of Mirati Therapeutics Inc (MRTX) is -5.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRTX's latest enterprise value is 3,859.11 mil USD. MRTX's TTM EBITDA according to its financial statements is -723.54 mil USD. Dividing these 2 quantities gives us the above MRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.5x - 14.3x | 12.8x |
| Forward P/E multiples | 11.1x - 16.7x | 13.6x |
| Fair Price | (115.13) - (143.39) | (132.46) |
| Upside | -296.1% - -344.3% | -325.7% |
| Date | EV/EBITDA |